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The U.S. FDA is currently reviewing AquaBounty Tech-
nologies’ New Animal Drug Application for a fast growing
transgenic Atlantic salmon, known as AquAdvantage®
Salmon, which would be the first genetically modified
food animal approved for human consumption. AquA-
dvantage® Salmon was developed by inserting into a ferti-
lized Atlantic salmon egg, a transgene constructed from
the growth hormone gene of a related species (Chinook
salmon). The AquAdvantage® genetic construct confers
upon the Atlantic salmon a rapid growth phenotype and
improved metabolic efficiencies associated with low but
sustained levels of growth hormone. This allows the fast
growing AquAdvantage® Salmon to reach market size in
half the time of a conventional Atlantic salmon. AquA-
dvantage® Salmon will be available only as all female, ster-
ile, eyed eggs, and the resulting fish must be maintained in
a freshwater, land based, physically contained facility [1].
The founding line of AquAdvantage® Salmon was cre-
ated in 1989, and an Investigational New Animal Drug
(INAD) dossier was opened with the FDA in 1995. In
2009, AquaBounty submitted to the FDA the last of more
than 25 scientific studies in support of our application. In
2010 the FDA presented their findings to the Veterinary
Medical Advisory Committee (VMAC), and recom-
mended an approval. The VMAC committee, comprised
of independent experts selected from academia, industry,
and NGO’s, concurred with the FDA’s findings, which
were that AquAdvantage® Salmon is equivalent to con-
ventional farmed Atlantic salmon, and is safe for human
consumption as well as safe for the environment. The
regulatory analysis included an environmental assessment
of a proposed AquAdvantage® Salmon egg production
site in Canada, and an AquAdvantage® Salmon growout
site in Panama, both of which were inspected and
approved by the FDA. Important biosecurity elements for
containing AquAdvantage® Salmon and minimizing
potential risk to the environment at the two production
sites include physical, biological, and environmental con-
tainment. For example, at the proposed growout site in
Panama which is more than 120 km from the nearest
ocean, sterile, all female populations of AquAdvantage®
Salmon are confined to a highly biosecure culture facility
possessing 21 individual containment elements, with a
minimum of eleven containment barriers in sequence. In
addition to the biological and physical containment ele-
ments, a natural thermal barrier of lethally high water
temperatures (for Atlantic salmon) downstream of
the facility would effectively prevent any live, escaped
AquAdvantage® Salmon from reaching the Pacific
Ocean.
In 2012 the FDA published the environmental assess-
ment for public commentary, and a Finding of No Sig-
nificant Impact (FONSI), indicating that rearing
AquAdvantage® Salmon in those sites did not present a
risk to the environment when reared under the conditions
of use stipulated by the FDA. The public comment period
concluded in April of 2013, and a final resolution of the
application is expected this year from the FDA. If approved
by the FDA, the product offered by AquaBounty would be
eyed eggs of AquAdvantage® Salmon, which would carry
an FDA approved label indicating that they are female, tri-
ploid, genetically engineered Atlantic salmon eggs carrying
a single copy of the AquAdvantage®gene construct. The
label would also stipulate that the fish from these eggs
could only be grown in pre-approved, land based, physically
contained, freshwater aquaculture facilities.
As a pioneering application for a genetically modified
animal destined for human consumption, AquAdvan-
tage® Salmon has attracted considerable attention and
opposition by anti-GMO, anti-biotech activist organiza-
tions, as well as the organic food industry which is
threatened by the more productive, lower cost, food
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production alternatives offered by GM plant and animal
biotechnology. Resigned to accepting the inevitable reg-
ulatory approval of GM salmon and other innovative
animal biotech products, the anti-GMO community is
now desperately resorting to labeling initiatives, and
economic extortion of future market stakeholders, in an
effort to commercially stigmatize genetically modified
food products.
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